Recent evidence from preclinical and at-risk human populations, such as APOE ε4 carriers, supports the relevance of these observations, but larger, well-controlled trials are necessary to confirm whether connectivity changes can serve as reliable early markers or treatment indicators in Alzheimer’s disease. Here, APOE is linked to early-onset autosomal dominant Alzheimer disease.